Filing Details

Accession Number:
0001140361-15-027836
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-07-16 21:19:11
Reporting Period:
2015-07-14
Filing Date:
2015-07-16
Accepted Time:
2015-07-16 21:19:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
926617 Vermillion Inc. VRML In Vitro & In Vivo Diagnostic Substances (2835) 330595156
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
924141 P L Partners Institutional Oracle C/O Oracle Investment Management, Inc.
200 Greenwich Avenue
Greenwich CT 06830
No No Yes Yes
926475 N Larry Feinberg C/O Oracle Investment Management, Inc.
200 Greenwich Avenue
Greenwich CT 06830
No No Yes Yes
941901 Oracle Partners Lp C/O Oracle Investment Management, Inc.
200 Greenwich Avenue
Greenwich CT 06830
No No Yes Yes
1012622 Oracle Investment Management Inc 200 Greenwich Avenue
Greenwich CT 06830
No No Yes Yes
1317217 Oracle Associates Llc C/O Oracle Investment Management, Inc.
200 Greenwich Avenue
Greenwich CT 06830
No No Yes Yes
1577258 Oracle Ten Fund Master, Lp C/O Oracle Investment Management, Inc.
200 Greenwich Avenue
Greenwich CT 06830
No No Yes Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.001 Per Share Acquisiton 2015-07-14 510,204 $1.96 8,624,225 No 4 P Indirect See footnote
Common Stock, Par Value $0.001 Per Share Acquisiton 2015-07-14 1,839 $1.91 8,624,225 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Warrants to acquire Common Stock $0.00 2015-06-23 2017-12-23 583,333 583,333 Indirect
Expiration Date Amount Remaning Holdings Nature of Ownership
2017-12-23 583,333 583,333 Indirect
Footnotes
  1. See Exhibit 99.1, Note 1.
  2. See Exhibit 99.1, Note 2.